NASDAQ:ONTX Onconova Therapeutics (ONTX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.67▼$1.0152-Week Range N/AVolume1.28 million shsAverage Volume96,681 shsMarket Capitalization$20.90 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesShort InterestTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesShort InterestTrends Get Onconova Therapeutics alerts: Email Address Ad The Oxford ClubDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research... But today, the author of Get Rich with Dividends is feeling extra generous...Click here now to claim your FREE copy of Marc's AI playbook. About Onconova Therapeutics Stock (NASDAQ:ONTX)Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.Read More Ad The Oxford ClubDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research... But today, the author of Get Rich with Dividends is feeling extra generous...Click here now to claim your FREE copy of Marc's AI playbook. ONTX Stock News HeadlinesJuly 20, 2024 | seekingalpha.comTRAW Traws Pharma, Inc.April 4, 2024 | uk.investing.comOnconova and Trawsfynydd merge to form Traws PharmaJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.April 4, 2024 | finance.yahoo.comTraws Pharma Full Year 2023 Earnings: Beats ExpectationsApril 3, 2024 | msn.comNewtown’s Onconova Therapeutics Secures $14 Million and New CEO in Merger with TrawsfynyddApril 2, 2024 | markets.businessinsider.comOnconova Acquires Trawsfynydd To Form Traws PharmaApril 2, 2024 | globenewswire.comTraws Pharma Announces New Employee Inducement GrantsMarch 12, 2024 | msn.comOnconova to Unveil New Rigosertib Study Results at Cancer Research MeetingJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.March 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX) and Biogen (BIIB)March 8, 2024 | finance.yahoo.comOnconova Therapeutics’ Rigosertib Poster Selected for AACR 2024March 8, 2024 | globenewswire.comOnconova Therapeutics' Rigosertib Poster Selected for AACR 2024February 13, 2024 | investing.comOnconova Therapeutics Inc (ONTX)January 23, 2024 | finance.yahoo.comOnconova Therapeutics, Inc. (ONTX)December 21, 2023 | benzinga.comOnconova Therapeutics Stock (NASDAQ:ONTX) Dividends: History, Yield and DatesDecember 12, 2023 | msn.comOnconova stock falls 10% on preclinical data for lymphoma drugDecember 12, 2023 | finance.yahoo.comOnconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell LymphomaDecember 8, 2023 | finance.yahoo.comOnconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’sSee More Headlines Receive ONTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today7/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ONTX CUSIPN/A CIK1130598 Webwww.onconova.com Phone(267) 759-3680Fax267-759-3681Employees16Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,960,000.00 Net Margins-8,930.97% Pretax Margin-8,930.97% Return on Equity-95.43% Return on Assets-61.19% Debt Debt-to-Equity RatioN/A Current Ratio2.79 Quick Ratio2.79 Sales & Book Value Annual Sales$230,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / BookN/AMiscellaneous Outstanding Shares21,000,000Free Float20,310,000Market Cap$20.90 million OptionableOptionable Beta1.38 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Steven M. Fruchtman M.D. (Age 73)CEO, President & Director Comp: $907.86kMr. Mark Patrick Guerin CPA (Age 55)CFO & COO Comp: $629.27kDr. Victor Moyo M.D.Chief Medical OfficerKey CompetitorsVaccinexNASDAQ:VCNXAssembly BiosciencesNASDAQ:ASMBCellectar BiosciencesNASDAQ:CLRBAllakosNASDAQ:ALLKMilestone PharmaceuticalsNASDAQ:MISTView All Competitors ONTX Stock Analysis - Frequently Asked Questions How were Onconova Therapeutics' earnings last quarter? Onconova Therapeutics, Inc. (NASDAQ:ONTX) released its quarterly earnings data on Thursday, November, 11th. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. The biopharmaceutical company earned $0.06 million during the quarter, compared to the consensus estimate of $0.06 million. Onconova Therapeutics had a negative net margin of 8,930.97% and a negative trailing twelve-month return on equity of 95.43%. When did Onconova Therapeutics' stock split? Onconova Therapeutics shares reverse split on Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Onconova Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST) and Bionano Genomics (BNGO). This page (NASDAQ:ONTX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconova Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Onconova Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.